VECTIVBIO HLDG AG's ticker is VECT and the CUSIP is H9060V101. A total of 52 filers reported holding VECTIVBIO HLDG AG in Q2 2023. The put-call ratio across all filers is 0.68 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $31,610,538 | +7.8% | 3,675,644 | +7.9% | 0.58% | +0.3% |
| Q4 2022 | $29,322,595 | +108.9% | 3,405,644 | +45.6% | 0.58% | +109.4% |
| Q3 2022 | $14,034,000 | +11.1% | 2,339,044 | 0.0% | 0.28% | +2.2% |
| Q2 2022 | $12,631,000 | +14.9% | 2,339,044 | 0.0% | 0.27% | +57.0% |
| Q1 2022 | $10,994,000 | -1.7% | 2,339,044 | 0.0% | 0.17% | +20.3% |
| Q4 2021 | $11,186,000 | -36.4% | 2,339,044 | 0.0% | 0.14% | -38.4% |
| Q3 2021 | $17,599,000 | -33.8% | 2,339,044 | -0.1% | 0.23% | -35.0% |
| Q2 2021 | $26,592,000 | – | 2,341,427 | – | 0.36% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 5,255,484 | $44,724,170 | 11.87% |
| TCG Crossover Management, LLC | 3,113,600 | $26,496,736 | 5.16% |
| CAXTON CORP | 156,651 | $1,345,549 | 3.40% |
| VR Adviser, LLC | 1,866,000 | $15,879,660 | 3.10% |
| Novo Holdings A/S | 3,610,461 | $30,725,023 | 2.03% |
| Cormorant Asset Management, LP | 2,536,617 | $21,587 | 1.42% |
| Vivo Capital, LLC | 2,333,300 | $19,856,383 | 1.38% |
| Orbimed Advisors | 5,156,561 | $43,882,334 | 0.86% |
| Frazier Life Sciences Management, L.P. | 1,352,199 | $11,628,911 | 0.84% |
| Bpifrance SA | 2,806,217 | $23,880,907 | 0.61% |